Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics and diagnostics to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. The company has drugs in clinical stage development for the treatment of fibromyalgia, PTSD, long covid, depression, PTSD, and neurocognitive dysfunction from corticosteroids, cocaine intoxication or overdose, and chronic migraine. In the preclinical stage, Tonix Pharmaceuticals is developing treatments for preventing organ transplant rejection, autoimmune disorders, gastric and colorectal cancers, Prader-Willi syndrome, and vaccines for COVID-19, smallpox, and monkeypox.

Tonix Pharmaceuticals is publicly traded on the NASDAQ under the stock symbol TNXP and is headquartered in Chatham, New Jersey. The CEO is cofounder Seth Lederman.

In July 2022, Tonix Pharmaceuticals announced a collaboration with the Kenya Medical Research Institute (KEMRI) to plan and seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop TNX-801 as a vaccine to protect against monkeypox and smallpox. The study is expected to start in the first half of 2023.

TNX-801 is a live virus vaccine based on synthesized horsepox. Tonix is developing the TNX-801 for percutaneous administration as a vaccine to protect against monkeypox and smallpox. The company has previously reported positive data from a monkeypox challenge study in non-human primates.

Tonix Pharmaceuticals's infectious disease portfolio also includes COVID-19 next-generation vaccines to prevent COVID-19, an antiviral to treat COVID-19, and a potential treatment for long covid. Tonix Pharmaceuticals has partnered with the non-profit research organization Southern Research for the development of the coronavirus vaccine TNX-1800 for the novel coronavirus outbreak, COVID-19. TNX-1800 is a modified horsepox virus designed to express a protein derived from the strain of coronavirus that causes COVID-19 disease. The efficacy of the vaccine will be evaluated by Southern Research.